Home › Research › Biomarkers
Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
Lu J, Ma X, Zhang H, Xiao Z, Li M, Wu J, Ju Z, Chen L et al.. Translational neurodegeneration, 2023-06-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer's disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. Methods A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging ( 18 F-florbetapir for A, 18 F-Florzolotau for T, and 18 F-fluorodeoxyglucose [ 18 F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. Results Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ- subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism - along with elevated plasma neurofilament light chain level - was related to more severe cognitive impairment in Aβ- subjects. Conclusion Plasma p-tau181, as well as 18 F-florbetapir and 18 F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. 18 F-Florzolotau and 18 F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lu, J., Ma, X., Zhang, H., Xiao, Z., Li, M., Wu, J., et al. (2023). Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints. Translational neurodegeneration. https://doi.org/10.1186/s40035-023-00365-x
Vancouver
Lu J, Ma X, Zhang H, Xiao Z, Li M, Wu J, et al. Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints. Translational neurodegeneration. 2023. doi:10.1186/s40035-023-00365-x. PMID: 37381042.
BibTeX
@article{lu2023-37381042,
author = {Lu, J. and Ma, X. and Zhang, H. and Xiao, Z. and Li, M. and Wu, J. and Ju, Z. and Chen, L. and others},
title = {{Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints}},
journal = {Translational neurodegeneration},
year = {2023},
doi = {10.1186/s40035-023-00365-x},
pmid = {37381042},
url = {https://doi.org/10.1186/s40035-023-00365-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances.
- Results Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort.
- An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects.
- Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants137
- Evidence strengthModerate
How this study scored 55/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 32 of the 58 points we could judge it on, which is 55 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Translational neurodegeneration) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 137 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37381042) |
| Free to read | 2 / 2 | Free to read |
| Points | 32 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 32 of the 58 points we could judge it on is 55 out of 100. |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.